Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).

Clinical research sites face challenges in managing the growing complexity of trials. The increasing administrative burden, protocol complexities, constant staff turnover, and operational ...

The diabetic macular edema section is a comprehensive resource for Ophthalmology news and expert insights. Read more at Modern Retina.

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025.

July 6th 2025 New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.